Answers are grounded in this paper and cite their sources.
5α-reductase inhibitors' potential benefits in preventing prostate cancer and potential increased risk for high-grade cancers have been central issues for the FDA, which convened its Oncologic Drugs Advisory Committee to address the topic last December.
No takes yet. Share an insight, caveat, or question.
Theoret et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: